RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Glutaminase 저해 항암제 개발의 최근 발전 사항들

        김규비(Gyubi Kim),주한솔(Hansol Joo),정종화(Jong-Wha Jung) 대한약학회 2021 약학회지 Vol.65 No.5

        Glutaminolysis is closely related to uncontrolled tumor growth and metastasis in various glutamine-dependent cancers. As such, rewiring cancer metabolism using a glutaminolysis intervention has attracted much attention with recent progress in developing glutaminase inhibitors as anticancer agents. This review paper described the current understanding of glutaminases and their roles in cancers and small-molecule glutaminase inhibitors. In particular, recent developments of natural and synthetic glutaminase inhibitors were covered, focusing on their binding sites and isoform selectivity and briefly, on their structure-activity relationship. Some of the glutaminase inhibitors are in clinical trials, and if successful, it would lead to novel pharmacological intervention to effectively treat cancers.

      • KCI등재

        2023년 FDA 승인 펩타이드 의약품

        정혜웅(Hye Ung Jeong),오창민(Changmin Oh),진효언(Hyo-Eon Jin),정종화(Jong-Wha Jung) 대한약학회 2024 약학회지 Vol.68 No.2

        Peptide drugs generally show high performance in terms of safety, target affinity, and efficacy, but have limitations such as low bioavailability and short half-life. To improve this, new synthetic and analytical techniques have been developed, and the global market for peptide drugs has made great strides in the past few years, with novel peptide drugs being applied to multiple therapeutic areas. In line with this trend, 5 out of 55 new molecular entities (NMEs) approved by the FDA in the year 2023 were peptide drugs, which is an increasing trend in the last few years. In this review article, we will discuss the mechanisms of action and clinical indications, chemical structure and design, and pharmacokinetic perspectives of 6 FDA-approved peptide drugs in 2023 including 5 NMEs.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼